Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Payables: 2009-2024

Historic Payables for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $2.1 million.

  • Ironwood Pharmaceuticals' Payables fell 50.15% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 46.60%. This contributed to the annual value of $2.1 million for FY2024, which is 72.84% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Payables stood at $2.1 million for FY2024, which was down 72.84% from $7.8 million recorded in FY2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Payables peaked at $7.8 million during FY2023, and registered a low of $483,000 during FY2022.
  • In the last 3 years, Ironwood Pharmaceuticals' Payables had a median value of $2.1 million in 2024 and averaged $3.5 million.
  • Its Payables has fluctuated over the past 5 years, first crashed by 83.38% in 2020, then skyrocketed by 1,521.12% in 2023.
  • MRY analysis of 5 years shows Ironwood Pharmaceuticals' Payables stood at $661,000 in 2020, then soared by 41.45% to $935,000 in 2021, then plummeted by 48.34% to $483,000 in 2022, then surged by 1,521.12% to $7.8 million in 2023, then crashed by 72.84% to $2.1 million in 2024.
  • Its last three reported values are $2.1 million in FY2024, $7.8 million for FY2023, and $483,000 during FY2022.